Advanced Medical Solutions Group (LSE:AMS) said it expects to report 2025 revenues of approximately £228.5 million, up from £177.5 million in the prior year, with EBITDA forecast in the range of £49.5 million to £50 million. The board said it remains confident of delivering results in line with market expectations.
The increase in revenue reflects strong demand across the group’s core surgical product categories, alongside an improving performance in the woundcare division. This more than offset ongoing destocking in the Peters Surgical B2B segment. Integration of both the Peters Surgical and Syntacoll acquisitions continues to progress according to plan, with early commercial synergies already being realised. Further operational benefits are expected to emerge from 2027 as integration matures.
Management noted that the group now operates with a broader and more resilient product portfolio, supported by an expanded international footprint following the Peters Surgical acquisition. Preparations to deepen penetration of the US market are well advanced, underpinning confidence in another solid year of growth in 2026. The company believes these factors position it well for scalable expansion, margin enhancement and sustained long-term value creation.
From an investment perspective, Advanced Medical Solutions continues to demonstrate strong top-line momentum and a sound capital structure. However, pressure on profitability margins remains a key consideration. Technical indicators point to positive share price momentum, while valuation metrics suggest the stock may be trading at elevated levels. Recent acquisition activity and investor engagement highlight the group’s longer-term growth ambitions.
More about Advanced Medical Solutions
Advanced Medical Solutions Group plc is a UK-based medical device specialist focused on tissue-healing technologies, including surgical adhesives, sealants, biosurgical products and sutures. Drawing on advanced materials science and applicator design developed in collaboration with surgeons, the group serves global surgical and woundcare markets. Its business model benefits from a diversified product range and geographic exposure, with a growing emphasis on direct sales following the acquisition of Peters Surgical to accelerate expansion in the US and other international markets.
Leave a Reply